ARVN
Arvinas, Inc. NASDAQ Listed Sep 27, 2018$10.19
Mkt Cap $651.8M
52w Low $5.90
49.8% of range
52w High $14.51
50d MA $11.43
200d MA $10.49
P/E (TTM)
-8.2x
EV/EBITDA
-8.4x
P/B
1.6x
Debt/Equity
0.0x
ROE
-18.6%
P/FCF
-2.8x
RSI (14)
—
ATR (14)
—
Beta
1.98
50d MA
$11.43
200d MA
$10.49
Avg Volume
835.4K
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
5 Science Park · New Haven, CT 06511 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 24, 2026 | BMO | -0.55 | -1.10 | -100.0% | 12.30 | -7.9% | +0.6% | +7.5% | +0.6% | -0.8% | +0.9% | — |
| Nov 5, 2025 | BMO | -0.75 | -0.48 | +36.0% | 9.54 | -1.2% | +0.3% | +4.5% | +6.3% | +5.3% | +0.2% | — |
| Aug 6, 2025 | BMO | -0.87 | -0.84 | +3.4% | 7.61 | -6.4% | -15.5% | -3.0% | +0.8% | +4.8% | +3.0% | — |
| May 1, 2025 | BMO | -0.86 | 1.14 | +232.6% | 9.62 | -33.9% | -24.8% | +6.8% | -1.2% | -8.9% | -4.0% | — |
| Feb 11, 2025 | BMO | -1.07 | -0.63 | +41.1% | 18.97 | -1.3% | -6.8% | +1.5% | -1.6% | +3.6% | +1.9% | — |
| Oct 30, 2024 | BMO | -0.88 | -0.68 | +22.7% | 27.50 | +0.7% | +0.6% | -4.4% | +1.8% | -0.4% | +0.4% | — |
| Jul 30, 2024 | BMO | -0.72 | -0.49 | +31.9% | 27.78 | +4.0% | -2.5% | +1.6% | -2.7% | -3.5% | -3.6% | — |
| May 7, 2024 | BMO | -1.48 | -0.97 | +34.5% | 32.26 | +0.4% | +6.4% | -5.7% | -1.3% | -1.6% | +0.4% | — |
| Feb 27, 2024 | BMO | -1.33 | -2.53 | -90.2% | 48.79 | +0.0% | -1.6% | -4.3% | +0.1% | +2.9% | -1.8% | — |
| Nov 7, 2023 | BMO | -1.52 | -1.18 | +22.4% | 16.93 | +1.0% | +5.1% | -7.2% | -8.2% | -1.1% | +10.7% | — |
| Aug 8, 2023 | BMO | -1.67 | -1.25 | +25.1% | 23.34 | +3.2% | +4.1% | -1.9% | +3.8% | +0.7% | +0.7% | — |
| May 5, 2023 | BMO | -1.46 | -1.54 | -5.5% | 23.51 | +2.0% | +7.6% | -2.5% | -1.9% | +0.0% | -5.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 19 | Citigroup | Maintains | Buy → Buy | — | $10.89 | $10.87 | -0.2% | +2.6% | -2.1% | -5.7% | -0.3% | +6.1% |
| Mar 19 | BTIG | Maintains | Buy → Buy | — | $10.89 | $10.87 | -0.2% | +2.6% | -2.1% | -5.7% | -0.3% | +6.1% |
| Mar 5 | Citigroup | Maintains | Buy → Buy | — | $13.76 | $13.72 | -0.3% | -0.3% | -0.9% | -1.7% | +3.4% | -2.5% |
| Feb 25 | Wedbush | Maintains | Neutral → Neutral | — | $12.37 | $12.98 | +4.9% | +7.5% | +0.6% | -0.8% | +0.9% | -0.2% |
| Feb 25 | Piper Sandler | Maintains | Overweight → Overweight | — | $12.37 | $12.98 | +4.9% | +7.5% | +0.6% | -0.8% | +0.9% | -0.2% |
| Feb 25 | Evercore ISI | Maintains | Outperform → Outperform | — | $12.37 | $12.98 | +4.9% | +7.5% | +0.6% | -0.8% | +0.9% | -0.2% |
| Jan 6 | Citigroup | Upgrade | Neutral → Buy | — | $11.17 | $12.74 | +14.1% | +5.9% | +4.9% | -1.9% | -0.9% | +0.7% |
| Dec 17 | Barclays | Maintains | Overweight → Overweight | — | $11.90 | $12.20 | +2.5% | -1.5% | -3.8% | +3.5% | +5.5% | -1.1% |
| Nov 10 | Stephens & Co. | Maintains | Overweight → Overweight | — | $10.63 | $10.80 | +1.6% | +5.3% | +0.2% | -7.1% | -2.8% | +4.4% |
| Nov 6 | Wells Fargo | Maintains | Overweight → Overweight | — | $9.57 | $9.71 | +1.5% | +4.5% | +6.3% | +5.3% | +0.2% | -7.1% |
| Nov 6 | Barclays | Maintains | Overweight → Overweight | — | $9.57 | $9.71 | +1.5% | +4.5% | +6.3% | +5.3% | +0.2% | -7.1% |
| Oct 30 | BTIG | Maintains | Buy → Buy | — | $9.59 | $9.88 | +3.0% | +3.5% | +2.1% | -4.1% | -1.9% | +0.3% |
| Oct 15 | Goldman Sachs | Downgrade | Neutral → Sell | — | $9.41 | $8.80 | -6.5% | +0.5% | +2.3% | -1.7% | +2.1% | -0.6% |
| Sep 18 | Stephens & Co. | Maintains | Overweight → Overweight | — | $7.61 | $7.82 | +2.8% | +1.4% | -2.6% | +0.1% | +0.0% | +2.7% |
| Sep 18 | BTIG | Maintains | Buy → Buy | — | $7.61 | $7.82 | +2.8% | +1.4% | -2.6% | +0.1% | +0.0% | +2.7% |
| Aug 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.43 | $6.64 | +3.3% | -3.0% | +0.8% | +4.8% | +3.0% | +4.4% |
| Aug 7 | Wells Fargo | Maintains | Overweight → Overweight | — | $6.43 | $6.64 | +3.3% | -3.0% | +0.8% | +4.8% | +3.0% | +4.4% |
| Aug 7 | Guggenheim | Maintains | Buy → Buy | — | $6.43 | $6.64 | +3.3% | -3.0% | +0.8% | +4.8% | +3.0% | +4.4% |
| Jun 2 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $7.20 | $6.74 | -6.4% | +1.8% | -4.5% | -0.7% | -0.4% | +8.8% |
| May 15 | UBS | Maintains | Buy → Buy | — | $6.07 | $6.11 | +0.7% | +3.1% | +3.7% | +0.6% | +1.7% | -5.9% |
| May 9 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $6.81 | $6.78 | -0.4% | -2.9% | -1.4% | -3.5% | -3.5% | +3.1% |
| May 5 | Citigroup | Maintains | Neutral → Neutral | — | $7.72 | $7.50 | -2.8% | -1.2% | -8.9% | -4.0% | +2.1% | -2.9% |
| May 5 | BMO Capital | Maintains | Outperform → Outperform | — | $7.72 | $7.50 | -2.8% | -1.2% | -8.9% | -4.0% | +2.1% | -2.9% |
| May 5 | Truist | Downgrade | Buy → Hold | — | $7.72 | $7.50 | -2.8% | -1.2% | -8.9% | -4.0% | +2.1% | -2.9% |
| May 2 | Wells Fargo | Maintains | Overweight → Overweight | — | $7.23 | $7.29 | +0.8% | +6.8% | -1.2% | -8.9% | -4.0% | +2.1% |
| May 2 | Jefferies | Downgrade | Buy → Hold | — | $7.23 | $7.29 | +0.8% | +6.8% | -1.2% | -8.9% | -4.0% | +2.1% |
| May 2 | Piper Sandler | Maintains | Overweight → Overweight | — | $7.23 | $7.29 | +0.8% | +6.8% | -1.2% | -8.9% | -4.0% | +2.1% |
| May 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.23 | $7.29 | +0.8% | +6.8% | -1.2% | -8.9% | -4.0% | +2.1% |
| May 2 | Guggenheim | Maintains | Buy → Buy | — | $7.23 | $7.29 | +0.8% | +6.8% | -1.2% | -8.9% | -4.0% | +2.1% |
| May 2 | Goldman Sachs | Maintains | Neutral → Neutral | — | $7.23 | $7.29 | +0.8% | +6.8% | -1.2% | -8.9% | -4.0% | +2.1% |
| May 2 | Barclays | Maintains | Overweight → Overweight | — | $7.23 | $7.29 | +0.8% | +6.8% | -1.2% | -8.9% | -4.0% | +2.1% |
| Apr 17 | Goldman Sachs | Maintains | Neutral → Neutral | — | $7.65 | $7.74 | +1.2% | +12.4% | +1.7% | +2.2% | +1.5% | +0.8% |
| Apr 9 | Truist | Maintains | Buy → Buy | — | $6.19 | $6.01 | -2.9% | +8.7% | -1.6% | +5.0% | +6.5% | +2.4% |
| Apr 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.56 | $6.32 | -3.7% | -2.9% | -2.8% | +8.7% | -1.6% | +5.0% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.55 | $8.55 | +0.0% | -1.4% | +3.2% | -3.2% | +3.3% | +3.4% |
| Mar 13 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $9.03 | $8.90 | -1.4% | -5.3% | -1.4% | +3.2% | -3.2% | +3.3% |
| Mar 13 | Guggenheim | Maintains | Buy → Buy | — | $9.03 | $8.90 | -1.4% | -5.3% | -1.4% | +3.2% | -3.2% | +3.3% |
| Mar 12 | Wells Fargo | Maintains | Overweight → Overweight | — | $8.30 | $8.39 | +1.1% | +8.8% | -5.3% | -1.4% | +3.2% | -3.2% |
| Mar 12 | Wedbush | Downgrade | Outperform → Neutral | — | $8.30 | $8.39 | +1.1% | +8.8% | -5.3% | -1.4% | +3.2% | -3.2% |
| Mar 12 | BofA Securities | Maintains | Buy → Buy | — | $8.30 | $8.39 | +1.1% | +8.8% | -5.3% | -1.4% | +3.2% | -3.2% |
| Mar 12 | BMO Capital | Maintains | Outperform → Outperform | — | $8.30 | $8.39 | +1.1% | +8.8% | -5.3% | -1.4% | +3.2% | -3.2% |
| Mar 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.56 | $10.58 | -39.7% | -52.7% | +8.8% | -5.3% | -1.4% | +3.2% |
| Mar 7 | Citigroup | Maintains | Neutral → Neutral | — | $18.06 | $17.97 | -0.5% | +1.2% | -3.9% | -52.7% | +8.8% | -5.3% |
| Feb 12 | Stifel | Maintains | Buy → Buy | — | $17.68 | $17.51 | -1.0% | +1.5% | -1.6% | +3.6% | +1.9% | -0.6% |
| Feb 12 | Oppenheimer | Maintains | Outperform → Outperform | — | $17.68 | $17.51 | -1.0% | +1.5% | -1.6% | +3.6% | +1.9% | -0.6% |
| Feb 12 | BMO Capital | Maintains | Outperform → Outperform | — | $17.68 | $17.51 | -1.0% | +1.5% | -1.6% | +3.6% | +1.9% | -0.6% |
| Feb 12 | Guggenheim | Maintains | Buy → Buy | — | $17.68 | $17.51 | -1.0% | +1.5% | -1.6% | +3.6% | +1.9% | -0.6% |
| Feb 7 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $19.10 | $19.11 | +0.1% | -2.1% | +1.4% | -6.8% | +1.5% | -1.6% |
| Feb 3 | Barclays | Maintains | Overweight → Overweight | — | $17.61 | $17.41 | -1.1% | -2.9% | +5.6% | +8.5% | -2.5% | -2.1% |
| Dec 12 | Guggenheim | Maintains | Buy → Buy | — | $22.54 | $22.23 | -1.4% | -12.4% | -1.2% | -2.6% | +0.6% | -2.6% |
No insider trades available.
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Arvanium's ARV-102 achieved meaningful LRRK2 degradation in Parkinson's patients, validating its novel brain-penetrating PROTAC approach and potentially de-risking its pipeline for neurodegenerative disease treatment.
Mar 18
8-K
Arvinas, Inc -- 8-K Filing
Arvinas reported Q4 2025 results and submitted its first NDA for a PROTAC degrader drug candidate, positioning the company for potential FDA approval of this novel drug class while refocusing its pipeline strategy.
Feb 24
8-K · 5.02
!!! Very High
Arvinas, Inc -- 8-K 5.02: Executive Change
Arvinas appointed Briggs Morrison and Randy Teel as presidents while John Houston resigned, signaling potential leadership restructuring that investors should monitor for strategic direction changes.
Feb 12
Data updated apr 24, 2026 7:05pm
· Source: massive.com